US Stock MarketDetailed Quotes

ETNB 89bio

Watchlist
  • 8.250
  • -0.330-3.85%
Close Apr 25 16:00 ET
  • 8.250
  • 0.0000.00%
Post 17:39 ET
785.60MMarket Cap-4125P/E (TTM)

About 89bio Company

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Company Profile

SymbolETNB
Company Name89bio
Listing DateNov 11, 2019
Issue Price16.00
Founded2018
CEOMr. Rohan Palekar
MarketNASDAQ
Employees70
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address142 Sansome Street,2nd floor
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94104
Phone1-415-432-9270
Websitehttp://www.89bio.com

Company Executives

  • Name
  • Position
  • Salary
  • Rohan Palekar
  • Chief Executive Officer and Director
  • 5.59M
  • Quoc Le-Nguyen
  • Chief Technical Operations Officer and Head of Quality
  • 2.51M
  • Dr. Hank Mansbach, M.D.
  • Chief Medical Officer
  • 2.54M
  • Ryan Martins
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Steven M. Altschuler, M.D.
  • Chairman of the Board
  • 385.83K
  • Martin Babler
  • Director
  • --
  • Dr. Derek DiRocco, PhD
  • Independent Director
  • 352.33K
  • Kathleen D. Laporte
  • Independent Director
  • 360.17K
  • Dr. Michael Hayden, Ch.B.,M.B.,PhD
  • Independent Director
  • 358.33K
  • Dr. Edward Morrow Atkinson, III
  • Independent Director
  • 354.60K
  • Lota S. Zoth, C.P.A.
  • Independent Director
  • 363.33K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg